Intrinsiqs

Is Denali Therapeutics Inc. overvalued?

Denali Therapeutics Inc. (DNLI) — key valuation metrics and fundamentals.

No verdict
Price
$20.39
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$3.24B
Dividend yield
0.0%
Return on equity
-55.3%
Sector
Healthcare

See the full interactive analysis →

Fair value compares DNLI's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.